Europe's STOXX 600 fell on Friday, dragged by technology and healthcare stocks, keeping the index on track for its fourth ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

In today’s health-conscious world, manufacturers across various sectors are reshaping their strategies to cater to evolving ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Opella is Sanofi’s consumer healthcare business unit focusing on over-the-counter medicines, vitamins, minerals, and supplements and includes brands such as Allegra, Doliprane, and Dulcolax.

French pharma giant Sanofi is selling off its consumer healthcare business Opella ... of over-the-counter medicines and dietary supplements and includes well-known brands like Allegra (fexofenadine) ...

Marketing for a healthcare ... “As a brand, we have moved ahead in terms of having our brand proposition as ‘Take Care’. We want to ‘Take Care’ of you as a consumer and as a patient.

Analysts fell to the sidelines weighing in on Sanofi (SNYNF – Research Report), Siegfried Holding AG (SGFEF – Research Report) and Terveystalo Oy (TTALF – Research Report) with neutral ...

Sanofi has entered exclusive negotiations to sell a 50% controlling stake in its consumer health business ... Opella, which houses brands including Allegra, generated sales of $5.7 billion ...